Exclusive speaker interview with Ester Lovsin Barle ahead of the 6th Annual High Potency Active Pharmaceutical Ingredients Conference

SMi Group reports: Exclusive speaker interview published with Takeda Pharmaceutical Company Ltd. in front of Very Powerful API Conference.

London, United Kingdom April 09, 2022 –(PR.com)– Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts, including EHS Chiefs and Directors, occupational hygiene, quality assurance and more. will take place on May 9 and 10 at London, UK.

With a focus on expanding your community and exploring the latest industry developments at this two-day event, including key regulatory updates and key case studies from leading pharmaceutical companies and biotechnology.

Register your spot online at: http://highlypotentapi.com/PR4PRCOM
SMi caught up Ester Lovsin BarleProduct Stewardship and Health Manager, Takeda Pharmaceutical Company Ltd. to discuss her role, priorities, current projects, opportunities and involvement as a speaker at the upcoming event.

Considering that high potency APIs continue to be an important aspect of pharmaceutical manufacturing, have you seen any changes regarding their handling or discussion in the past year?
The health and safety of employees is always a top priority for our company. On the business side, we strive to develop and integrate management systems into site operations, particularly those handling compounds that may pose higher risks due to their inherent hazards. Although there have been many discussions during the COVID-19 pandemic about the relevance of risks versus hazards, the difference remains a challenge to communicate.

What is the biggest challenge you personally face in the Highly Potent API space right now?
There has been a shift in operations to include new technologies and to use old technologies in a more sustainable way. At Takeda, we strive to be a leader in sustainability. The combination of sustainability thinking and health protection requires experts from both sides to have a common conversation, not to move risks up the value chain. An example of these synergies was recently published by Schmidt and Guytingco in an article titled Ventilation and sustainable laboratories (https://synergist.aiha.org/202202-sustainable-laboratories)

What topic will you address in your presentation and what would you say will make it relevant to the audience in 2022?
The subject of safety limits is reaching us more and more. We know our planetary limits, and we also have limits for the chemicals we are exposed to. I will talk about these limits.

Ester will present the first day of the conference on “The Dangers and Power of New Therapeutic Modalities” which covers:
Assess the relevance, adequacy and reliability of data
Determination of exposure limits in the absence of data
Nucleic Acids Case Study

Download the brochure at: http://highlypotentapi.com/PR4PRCOM

SMi offers sponsorship, exposure, advertising and branding packages, specially designed to complement your company’s marketing strategy. For further details and all delegate enquiries, please contact Luke teach on +44 (0) 20 7827 6002 or [email protected]

6th edition of SMi Conference on High Potency Active Pharmaceutical Ingredients
Conference: 9th – May 10, 2022
Interactive workshops: May 11, 2022
London, UK
http://highlypotentapi.com/PR4PRCOM

On SMi Group:
Established since 1993, the SMi Group is a global event production company specializing in B2B conferences, workshops, masterclasses and online communities. We create and organize events in the defense, security, energy, utilities, finance and pharmaceutical sectors. We pride ourselves on having access to the world’s most forward-thinking thought leaders and visionaries, enabling us to bring our communities together to learn, engage, share and network. More information can be found at http://www.smi-online.co.uk

Contact information:
SMi Group
Nikisha Galoria
+44 (0) 20 7827 6154
Contact by email
http://highlypotentapi.com/PR4PRCOM

Read the full story here: https://www.pr.com/press-release/858884

Press release distributed by PR.com

Copyright © 2022 PR.com and its licensors, source US press releases